Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling

BACKGROUND: Resistance to standard therapy is a major reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Developing novel therapy to overcome PDAC drug-resistance is urgently needed. CRABP-II was highly expressed in all PDAC but not expressed in normal pancreatic tissues and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shuiliang, Wang, Lei, Che, Danian, Zhang, Mei, Li, Ming, Naito, Mikihiko, Xin, Wei, Zhou, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903155/
https://www.ncbi.nlm.nih.gov/pubmed/35260193
http://dx.doi.org/10.1186/s13046-022-02261-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903155/
https://www.ncbi.nlm.nih.gov/pubmed/35260193
http://dx.doi.org/10.1186/s13046-022-02261-0

Ejemplares similares